Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma
Abstract
Background: Ki‐67 is routinely used in clinical practice to quantify proliferative activity, yet proliferation has not been incorporated into current molecular classification systems for urothelial carcinoma (UC). This work studies the tumor microenvironment (TME), therapeutic vulnerabilities, and clinical implications of the proliferative ecotype in UC. Methods: The authors assembled a multi‐cohort data set of 1431 UC patients from four institutional cohorts and five publicly available data sets with comprehensive clinicopathological annotations. Through an integrated multi‐omics framework coupled with experimental validation, they assessed how proliferative status shape lineage differentiation, clinical outcomes, treatment response, and TME architecture. Results: High Ki‐67 expression identified a proliferative ecotype associated with markedly worse prognosis but enhanced sensitivity to platinum‐based chemotherapy and PD‐1/PD‐L1 blockade. This ecotype displayed elevated tumor purity and tumor mutation burden, with characteristic genomic alterations including enrichment of TP53 , ERCC2 , and ATM/RB1/FANCC mutations and reduced 9p21.3 loss. The proliferative ecotype orchestrated an immune‐enriched TME dominated by CD8 + T cells and B cells. Functional analyses revealed that CD8 + T cells preferentially differentiated toward an exhausted state, and mechanistic interrogation identified a GDF‐15–TGFBR2 signaling axis through which epithelial cells modulate CD8 + T‐cell dysfunction. Conclusions: This study identifies a proliferative ecotype of UC that is orthogonal to classical luminal/basal ecotypes. Despite its adverse prognosis, this ecotype confers superior responsiveness to chemotherapy and immunotherapy and features a distinct genomic and immune ecosystem. These findings position proliferative status as a clinically actionable axis that may refine molecular classification and guide precision therapy in UC.Keywords
Funding Information
- National Natural Science Foundation of China (82272786)
- National Natural Science Foundation of China (82272930)
- National Natural Science Foundation of China (82372793)
- National Natural Science Foundation of China (82373276)
- National Natural Science Foundation of China (82503736)
- National Natural Science Foundation of China (82573675)
- China Postdoctoral Science Foundation (2024M760547)
- China Postdoctoral Science Foundation (2025M781936)
- China Postdoctoral Science Foundation (BX20230091)
- Beijing Xisike Clinical Oncology Research Foundation (Y‐Gilead2024‐PT‐0098)
- Beijing Xisike Clinical Oncology Research Foundation (Y‐QLMS2025‐0040)
This publication has 29 references indexed in Scilit:
- Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockadeCancer Cell, 2024
- PDGFRα+ITGA11+ fibroblasts foster early-stage cancer lymphovascular invasion and lymphatic metastasis via ITGA11-SELE interplayCancer Cell, 2024
- TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1/PD‐L1 blockade response in urothelial carcinomaThe Journal of Pathology, 2024
- Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancerCancer Cell, 2022
- NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancerCancer Cell, 2022
- Conserved pan-cancer microenvironment subtypes predict response to immunotherapyCancer Cell, 2021
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaCell, 2018
- Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint BlockadeCell Reports, 2017
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline ChemotherapyCancer Cell, 2014
- Hallmarks of Cancer: The Next GenerationCell, 2011